Bristol Myers Squibb Company (BMY) vs Organon & Co. (OGN)
- Bristol Myers Squibb Company BMY 59.71 −1.42%
- Organon & Co. OGN 13.76 0.00%
Bristol Myers Squibb Company and Organon & Co. are both Drug Manufacturers General companies. Bristol Myers Squibb Company is the larger, with a market value of $123.7B against $3.6B — 34.3× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.2× against 17.4×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 3.11% against −2.45%. Bristol Myers Squibb Company has the higher net margin (18.9% vs 3.41%) and the higher return on invested capital (13.7% vs 6.11%). Both pay a dividend; Bristol Myers Squibb Company yields more (4.22% vs 0.58%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 16 and Organon & Co. on 7.
Valuation
Profitability
| Metric | BMY | OGN | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 52.68% | 72.77% |
| Operating margin | 24.22% | 13.45% | 18.77% |
| Net margin | 18.87% | 3.41% | 8.27% |
| Free cash flow margin | 23.26% | 7.57% | 17.18% |
| Return on equity | 46.63% | 24.04% | 5.87% |
| Return on assets | 10.18% | 1.57% | 2.57% |
| Return on invested capital | 13.69% | 6.11% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack